Phase 2 Randomized Study to Compare Ultrasonic Drug Delivery to Standard of Care for the Treatment of Infections in Non-Healing Wounds

NCT03732365 | Unknown Phase 2 DMC FDA Drug FDA Device

• 1 other identifier: SON2018-001
• Study Type: interventional
• Target: 30
• Locations: 0 countries
• Sites: N/A

Brief Summary

This is a randomized study to compare the safety and efficacy of a single dose of up to 2 grams of cefazolin administered using a new drug delivery method called Ultrasonic Drug Delivery (UDD), combined with standard of care (SOC) antibiotic therapy, oral or IV, compared to standard of care (SOC) antibiotic therapy alone, in treating chronic wounds with skin and soft tissue infection, containing gram-positive pathogens, in lower extremities.

Conditions

Acute Bacterial Skin and Skin Structure Infection (ABSSSI); Non-healing Wound

Outcome Measures

Primary Outcomes (2)

• Wound healing and eligibility for grafting

  Number of wounds 100% granulation/ready to graft as assessed by a blinded observer

  12 weeks

• Reduction or elimination of pain

  Pain assessed by participant questionnaire

  12 weeks

Secondary Outcomes (1)

• Clinical signs and symptoms of infection will be assessed

  Day 9 and Day 91

Study Arms (2)

Investigational Group

EXPERIMENTAL

Patients who are randomized to the investigational regimen will receive Ultrasonic Drug Delivery, which includes infusion of up to 2 grams of cefazolin in 100 mL saline followed by external ultrasound in addition to standard of care antibiotic treatment according to the antibiotic package insert instructions for the particular gram-positive pathogen over a period of no more than 14 days as well as standard of care adjunct therapy.

Combination Product: Ultrasonic Drug Delivery

Comparator Group

ACTIVE COMPARATOR

Patients who are randomized to the comparator regimen will receive antibiotic according to the antibiotic package insert instructions for standard of care for the particular gram-positive pathogen over a period of no more than 14 days as well as standard of care adjunct therapy.

Drug: Standard of Care Antibiotic Treatment

Interventions

Ultrasonic Drug Delivery COMBINATION_PRODUCT

A maximum dose of 2 grams cefazolin in a solution of 1 gram/100 mL sterile saline will be injected into the affected area, followed by a 3-minute application of external ultrasound delivered at an acoustic intensity equal to 3 watts/square centimeter of surface area.

Also known as: Cefazolin with external ultrasound

Investigational Group

Standard of Care Antibiotic Treatment DRUG

Antibiotic treatment according to the antibiotic package insert instructions for the particular gram-positive pathogen over a period of no more than 14 days.

Comparator Group

Eligibility Criteria

• Age: 18 Years - 80 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Provision of signed and dated informed consent form
• Stated willingness to comply with all study procedures and availability for the duration of the study
• Must have a non-healing wound which shows clinical signs of infection characterized by erythema and at least two of the following signs of infection: Induration/swelling; Purulent drainage/discharge; Fluctuance; Heat/localized warmth; Tenderness/pain to palpation
• Patient must have one (1) or more of the following confirmed infection types of the lower extremity: a) Cellulitis/erysipelas: A diffuse skin infection characterized by spreading areas of redness, edema, and/or induration; b) Wound infection: An infection characterized by purulent drainage from a wound with surrounding redness, edema, and/or induration; c) Major cutaneous abscess: An infection characterized by a collection of pus within the dermis or deeper that is accompanied by redness, edema, and/or induration
• A minimum affected area that involves: At least 75cm2 of erythema; and is defined by a margin of erythema in at least one (1) direction that is ≥ 5 cm from the edge of the wound.
• In addition to the requirement for erythema, all patients are required to have at least two (2) of the following signs of acute bacterial skin and skin structure infection (ABSSSI): a) Purulent drainage/discharge; b) Fluctuance; c) Heat/localized warmth; d) Tenderness to palpation; and e) Swelling/induration
• Patients must present with at least ONE (1) of the following systemic signs of infection: a) An elevated body temperature ≥ 100.4 Fahrenheit as measured by clinical staff or investigator within 24 hours of baseline at screening; and/or b) White blood cell count \> 12,000 cells/mm3; c) manually performed white blood differential count with ≥ 10% band forms, regardless of peripheral white blood cell count.
• Bacteria culture positive for gram positive bacteria.
• Ability and willingness to accept subcutaneous administration of antibiotic and local anesthesia.
• For females of reproductive potential: use of highly effective contraception and agreement to use such a method during study participation.
• Agreement to adhere to the study intervention regimen.

You may not qualify if:

• Patients with conditions that would alter the interpretation of a primary endpoint, including: patients with neutropenia; and/or patients with peripheral neuropathy
• Participation in another study of an investigational drug or device within 30 days prior to administration of investigational treatment.
• Pregnant or lactating women.
• Patients with a known allergic reaction or hypersensitivity to cefazolin or penicillin.
• Infections caused exclusively by gram-negative bacteria (without gram-positive bacteria present) and infections caused by fungi, whether alone or in combination with a bacterial pathogen.
• Presence of gram-negative bacteremia, even in the presence of gram-positive infection or gram-positive bacteremia.
• Patients with evidence of meningitis, gas gangrene, gangrene, septic arthritis, or osteomyelitis, endovascular infection, such as clinical and/or echocardiographic evidence of endocarditis or septic thrombophlebitis.
• Infections involving a diabetic foot ulceration, perirectal abscess or a decubitus ulcer.
• Patients with an infection involving a limb with evidence of critical ischemia of an affected limb defined as any of the following criteria: absent or abnormal Doppler wave forms, toe blood pressure of \<45 mm Hg, ankle brachial index \<0.4, critical ischemia as assessed by a vascular surgeon.
• Patient with an infected device.
• Suspicion of skin cancer at the wound site (i.e., clinical evaluation is currently on-going).
• Patients who have a history of clinically significant or uncontrolled cardiac disease, including congestive heart failure, angina, myocardial infarction, arrhythmia, including New York Heart Association (NYHA) functional classification of III (marked limitation of physical activity comfortable at rest but less than ordinary activity results in fatigue, palpitation or dyspnoea) or Class IV (unable to carry out any physical activity without discomfort - symptoms at rest. If any physical activity is undertaken, discomfort is increased).
• Patients who have any other life-threatening illness or organ system dysfunction, which, in the opinion of the Investigator, would either compromise patient safety or interfere with the evaluation of the safety of the test drug.
• Anticipated need of antibiotic therapy for longer than 14 days.
• Medical conditions in which chronic inflammation may preclude assessment of clinical response to therapy even after successful treatment (e.g., chronic stasis dermatitis of the lower extremity).

Sponsors & Collaborators

• Sonescence, Inc.: lead
• University of Southern California: collaborator

MeSH Terms

Interventions

Cefazolin

Intervention Hierarchy (Ancestors)

Cephalosporins; beta-Lactams; Lactams; Amides; Organic Chemicals; Thiazines; Sulfur Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Heterocyclic Compounds

Study Officials

• David G Armstrong, Ph.D., DPM

  University of Southern California

  PRINCIPAL INVESTIGATOR

Central Study Contacts

David G Armstrong, Ph.D., DPM

CONTACT

(213) 740-2311; armstrong@usa.net

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: SINGLE
• Who Masked: OUTCOMES ASSESSOR
• Masking Details: This study will be observer-blinded. Each investigational site will be required to have a Sponsor-approved plan (a site-specific Blinding Plan) that describes site-specific precautions being taken to ensure that the study is observer-blinded, taking into account the specific subject care procedures, equipment, and information accessibility at that site. At each investigational site, at least 1 blinded investigator (referred to as "Blinded Observer") will not know the subject's treatment assignment and will conduct clinical assessments (including efficacy and safety. The Blinded Observer will not ask other members of the study team, the subject, or the subject's parent(s)/legally acceptable representative(s) which study treatment is being given, and will avoid all attempts to uncover treatment assignment. The Blinded Observer will see the subject during times when study treatment is NOT being administered.
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Model Details: Single-center, parallel-group study to compare the efficacy and safety of UDD plus standard of care with standard of care alone for the treatment of skin and soft tissue infections in chronic non-healing wounds.

Study Record Dates

• First Submitted: October 25, 2018
• First Posted: November 6, 2018
• Study Start: February 1, 2019
• Primary Completion: January 31, 2020
• Study Completion: July 31, 2020
• Last Updated: November 6, 2018

Record last verified: 2018-11